The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
biogen raises earnings forecast amid strong sales of new products
Biogen raised its diluted earnings per share guidance for the year to $16.10-$16.60, driven by strong sales of new products like Leqembi, which generated $67 million in Q3, a 66% increase from the previous quarter. Despite this, total revenue is expected to decline in 2024, with ongoing challenges in its multiple sclerosis drug sales. The company is undergoing significant transformation under CEO Chris Viehbacher, focusing on cost-cutting and diversifying its research portfolio.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.